Recent progress in the development of antagonists to the chemokine receptors CCR3 and CCR4

@article{Pease2014RecentPI,
  title={Recent progress in the development of antagonists to the chemokine receptors CCR3 and CCR4},
  author={James Edward Pease and Richard Horuk},
  journal={Expert Opinion on Drug Discovery},
  year={2014},
  volume={9},
  pages={467 - 483}
}
  • J. Pease, R. Horuk
  • Published 22 April 2014
  • Medicine
  • Expert Opinion on Drug Discovery
Introduction: The chemokine receptors CCR3 and CCR4 have been shown to be important therapeutic targets for the treatment of a variety of diseases. Although only two chemokine receptor inhibitors have been approved so far, there are numerous compounds that are in various stages of development. Areas covered: In this review article, the authors provide an update on the progress made in the identification of antagonists against the chemokine receptors CCR3 and CCR4 from 2009 to the present. The… 
Targeting chemokine receptors in disease – a case study of CCR4
TLDR
The discovery of the receptors and their ligands, their perceived roles in disease and the successful targeting of CCR4 by both small molecule antagonists and monoclonal antibodies are reviewed.
Novel Piperidinyl-Azetidines as Potent and Selective CCR4 Antagonists Elicit Antitumor Response as Single Agent and in Combination with Checkpoint Inhibitors.
TLDR
Small molecule antagonists of CCR4, featuring a novel piperidinyl-azetidine motif, are developed that inhibit the recruitment of Treg into the TME, and elicit anti-tumor responses as a single agent or in combination with immune checkpoint blockade.
Successes and failures of chemokine-pathway targeting in rheumatoid arthritis
TLDR
Preclinical studies carried out in animal models of arthritis involving agents targeting chemokines and chemokine receptors with promising results have yielded promising results, however, most human trials of treatment of RA with antibodies and synthetic compounds targetingChemokine signalling have failed to show clinical improvements.
"Chemokine receptors as therapeutic targets: Why aren't there more drugs?".
TLDR
Potential reasons for previous failures with chemokine receptors are discussed and also why there is considerable cause for optimism.
Discovery of a Potent and Selective CCR4 Antagonist That Inhibits Treg Trafficking into the Tumor Microenvironment.
TLDR
A novel series of potent, orally bioavailable small molecule antagonists of CCR4 is developed that exhibited high potency in distinct functional assays in addition to good in vitro and in vivo ADME properties.
CCR4 and its ligands: from bench to bedside.
TLDR
A brief overview of basic and clinical research on CCR4 and its ligands, which has eventually led to the development of a humanized defucosylated anti-CCR4 antibody 'Mogamulizumab' for treatment of relapsed/refractory ATL and CTCLs.
Development of therapeutic antibodies to G protein‐coupled receptors and ion channels: Opportunities, challenges and their therapeutic potential in respiratory diseases
TLDR
A summary of the importance of GPCRs and ion channels involved in respiratory disease and advantages offered by antibodies as therapeutics at these targets are provided.
Systematic Assessment of Chemokine Signaling at Chemokine Receptors CCR4, CCR7 and CCR10
TLDR
Comparisons with previous studies indicates that differential agonism at CCR4, CCR7 and CCR10 may be highly dependent on the cellular context, and the intrinsic abilities of different receptors to couple with different downstream signaling pathways are emphasized.
Progress in pharmacological research of chemokine like factor 1 (CKLF1)
TLDR
Collecting data derived from the and other laboratories show that CKLF1 has an important relationship with allergic diseases, autoimmune diseases, tumors, cardio‐cerebrovascular diseases and so on, and there be an important theoretical purport and applied value to make a summary of pharmacological progress of CKF1.
The C-C Chemokines CCL17 and CCL22 and Their Receptor CCR4 in CNS Autoimmunity
TLDR
An overview of the involvement of C CR4 and its ligands in CNS autoimmunity is provided and the therapeutic potential of newly developed CCR4 antagonists and a humanized anti-CCR4 antibody for treatment of MS is discussed.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 146 REFERENCES
Chemokine receptor antagonists: Part 1
TLDR
Although there has been no clinical success yet for antagonists targeting the group of receptors discussed here, the compounds have been invaluable in generating information that should pave the way for producing successful therapeutics in the future.
Small molecule antagonists of chemokine receptors--is promiscuity a virtue?
TLDR
The successes and failures of chemokine receptor antagonists in the clinic are discussed, a subset of molecules that are documented as having activity at two or more chemokines are reviewed and it may be that a more permissive approach, targeting several chemokin receptors with a single molecule will provide the next generation of anti-inflammatory drugs.
Distinct Conformations of the Chemokine Receptor CCR4 with Implications for Its Targeting in Allergy
TLDR
It is shown that CCL17 and CCL22 are conformationally selective ligands of CCR4 and interact with the receptor by substantially different mechanisms, which suggests that the selective blockade of C CR4 in allergy may be feasible when one CCL4 ligand dominates.
Small molecule antagonists for chemokine CCR3 receptors
TLDR
This review describes the structure–activity relationships (SAR) of small molecule CCR3 antagonists as reported in the scientific and patent literature and suggests the (N‐ureidoalkyl)benzylpiperidines are the best studied class in view of their generally high affinity and antagonizing potential.
Chemokine receptor antagonists: overcoming developmental hurdles
  • R. Horuk
  • Biology, Medicine
    Nature Reviews Drug Discovery
  • 2009
TLDR
Some of the recent failures in the clinical trials of chemokine receptor antagonists are highlighted and possible reasons include the lack of predictability of animal models and redundancy of the target.
CCR3 antagonists: a survey of the patent literature
TLDR
A patent literature review is presented of small molecule CCR3 antagonists comprising the years 2004 to the present, revealing diverse chemical classes of potent C CR3 antagonists and reflecting a continued broad interest in this area.
Overcoming hurdles in developing successful drugs targeting chemokine receptors
TLDR
It is proposed that inappropriate target selection and ineffective dosing, not the 'redundancy' of the chemokine system, are the main barriers to their use as anti-inflammatory therapies.
Targeting chemokine receptors in allergic disease.
  • J. Pease
  • Biology, Medicine
    The Biochemical journal
  • 2011
TLDR
The roles of chemokines and their receptors in allergic disease are detailed and current progress in the development of relevant chemokine receptor antagonists are highlighted.
Discovery of CC chemokine receptor-3 (CCR3) antagonists with picomolar potency.
TLDR
The benzenesulfonate salt of 32, designated DPC168, entered phase I clinical trials on the basis of its overall potency, selectivity, efficacy, and safety profile, and is a potent and selective antagonist of CCR3.
Asthma, allergy and chemokines.
  • J. Pease
  • Biology, Medicine
    Current drug targets
  • 2006
TLDR
Impaired recruitment by selective blockade of the CCR3:eotaxin axis represents an attractive target for the therapeutic treatment of asthma and the roles of other chemokine:chemokine receptor axes implicated in leukocyte recruitment during allergic inflammation are highlighted.
...
1
2
3
4
5
...